170359-24-7

Upstream product

• 100-39-0 benzyl bromide 
• 111060-52-7 (S)-2-(dibenzylamino)-3-phenylpropan-1-ol 
• 118970-37-9 (2S,3S)-3-(dibenzylamino)-2-hydroxy-4-phenylbutanenitrile 
• 63-91-2 L-phenylalanine 
• 95437-43-7 (S)-2-(N,N-dibenzylamino)-3-phenylpropanoic acid 
• 118970-36-8 (2R,3S)-3-(dibenzylamino)-2-hydroxy-4-phenylbutanenitrile 
• 123054-12-6 (2S)-N,N-dibenzylphenylalaninal 
• 244641-41-6 (2R,3S)-3-(dibenzylamino)-1-nitro-4-phenylbutan-2-ol 

Downstream Products

• 244641-42-7 N-(3-dibenzylamino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzenesulfonamide 
• 169280-56-2 4-amino-N-(2R,3S)(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutylbenzenesulfonamide 
• 169331-42-4 βS--αR-<<(2-methylpropyl)amino>methyl>-benzenepropanol 

Relevant academic research and scientific papers

Design, synthesis and evaluation of the antibacterial activity of new Linezolid dipeptide-type analogues

Worldwide studies towards development of new drugs with a lower rate in emergence of bacterial resistance have been conducted. The molecular docking analysis gives a possibility to predict the activity of new compounds before to perform their synthesis. In this work, the molecular docking analysis of 64 Linezolid dipeptide-type analogues was performed to predict their activity. The most negative scores correspond to six Fmoc-protected analogues (9as, 9bs, 9bu, 10as, 10ax and 10ay) where Fmoc group interacts in PTC for Linezolid. Twenty-six different Fmoc-protected Linezolid dipeptide-type analogues 9(as-bz) and 10(as-bz) were synthesized and tested in antimicrobial experiments. Compounds 9as, 9ay, 9ax, 10as, 10ay and 9bu show significant activity against group A Streptococcus clinical isolated. Analogue 10ay also display high activity against ATCC 25923 Staphylococcus aureus strain and MRSA-3, MRSA-4 and MRSA-5 clinical isolates, with MIC values lower than Linezolid. The highest activity against multidrug-resistant clinical isolates of Mycobacterium tuberculosis was exhibited by 9bu. Finally, a cytotoxicity assay with ARPE-19 human cells revealed a non-cytotoxic effect of 9bu and 10ay at 50 and 25 μM, respectively.

An Efficient Synthesis of a Hydroxyethylamine (HEA) Isostere and Its α-Aminophosphonate and Phosphoramidate Derivatives as Potential Anti-HIV Agents

HIV protease is a promising drug target for AIDS therapy, and several potent HIV-1 protease inhibitors have been reported to date. Although existing inhibitors exhibit high selectivity, they have also been associated with severe side effects and the possi

Anti- and syn-selective cyanosilylation reactions promoted by a sugar-based bifunctional catalyst: Stereoselective syntheses of essential building blocks for HIV protease inhibitors and bestatin

Chiral bifunctional catalyst 6 promoted anti- and syn-selective cyanosilylation reactions from chiral amino aldehydes derived from phenylalanine in excellent yields. Thus, from dibenzyl protected amino aldehyde 9, syn isomer was obtained as the major prod

re- and si-face-selective nitroaldol reactions catalyzed by a rigid chiral quaternary ammonium salt: A highly stereoselective synthesis of the HIV protease inhibitor amprenavir (Vertex 478)

Either amprenavir (1) or its C(2) diastereomer can be synthesized in a simple way by the use of a nitroaldol reaction carried out in the presence of one or the other of the two ammonium ions 2. The 1,3-diamino-2-hydroxypropyl structural element of 1 is also found in many other peptidomimetics and HIV protease inhibitors. Described here is a new strategy for possible application to direct and stereocontrolled synthesis of such compounds.

PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES

Disclosed herein are compounds which inhibit human immunodeficiency virus (HIV) protease activity and inhibit HIV replication in human cells. Thus, the compounds are indicated for the treatment of HIV infections. The compounds can be represented by the fo